Cariprazine
Vraylar (brand name)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Schizophrenia | Adults and adolescents ≥13 years | Monotherapy | FDA Approved |
| Bipolar I — acute manic/mixed episodes | Adults and pediatric patients ≥10 years | Monotherapy | FDA Approved |
| Bipolar I depression | Adults | Monotherapy | FDA Approved |
| Major depressive disorder | Adults | Adjunctive to antidepressants | FDA Approved |
Cariprazine was first approved in 2015 and is the only atypical antipsychotic with FDA-approved indications across all four major psychotic and mood disorder categories: schizophrenia, bipolar mania, bipolar depression, and adjunctive MDD. Its pharmacology is distinguished by D3 receptor-preferring partial agonism, with 6–8-fold greater affinity for D3 over D2 receptors, a profile unique among antipsychotics. The December 2025 label update added pediatric indications for schizophrenia (ages 13–17) and bipolar mania (ages 10–17), along with new lower capsule strengths (0.5 mg, 0.75 mg) to support paediatric dosing and CYP3A4 inhibitor dose adjustments.
Predominant negative symptoms of schizophrenia — Cariprazine showed benefit in a dedicated RCT (RGH-188-005) and is considered by some experts to have a specific advantage here due to D3 partial agonism. Evidence quality: Moderate.
Autism-related irritability — Under active investigation (FDA pediatric study requirement); not yet approved. Evidence quality: Low (ongoing).
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Schizophrenia | 1.5 mg QD | 1.5–6 mg QD | 6 mg/day | May increase to 3 mg on Day 2; adjust in 1.5–3 mg increments Doses above 6 mg do not confer additional benefit but increase AE risk |
| Bipolar I mania/mixed — acute | 1.5 mg QD | 3–6 mg QD | 6 mg/day | Increase to 3 mg on Day 2; further adjust in 1.5–3 mg increments |
| Bipolar I depression | 1.5 mg QD | 1.5 or 3 mg QD | 3 mg/day | Increase to 3 mg on Day 15; slower titration than schizophrenia/mania Lower dose range reflects depressive episode pharmacology |
| MDD — adjunct to antidepressant | 1.5 mg QD | 1.5 or 3 mg QD | 3 mg/day | Increase to 3 mg on Day 15; titration <14 days associated with more adverse reactions |
Paediatric Dosing by Clinical Scenario (December 2025 Label)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Schizophrenia — adolescent (13–17 years) | 0.5 mg QD | 1.5–4.5 mg QD | 4.5 mg/day | Increase to 1.5 mg on Day 3; may increase to 3 mg on Day 5, then 4.5 mg on Day 8 |
| Bipolar I mania/mixed (10–17 years) | 0.5 mg QD | 3 or 4.5 mg QD | 4.5 mg/day | Increase to 1.5 mg on Day 3, then 3 mg on Day 5; may increase to 4.5 mg on Day 8 |
The effective half-life of cariprazine’s total active moieties is approximately one week, which is far longer than most oral antipsychotics. This has critical clinical implications: (1) dose changes take several weeks to reach new steady state; (2) adverse reactions may first appear weeks after initiation, not immediately; (3) effects persist for weeks after discontinuation. Prescribers must monitor for adverse reactions and response for several weeks after each dose change, not just days. Additionally, cariprazine does not require food for absorption, unlike ziprasidone or lurasidone.
Pharmacology
Mechanism of Action
Cariprazine is a D3 receptor-preferring D3/D2 partial agonist — a pharmacological profile unique among available antipsychotics. It displays 6–8-fold greater binding affinity for D3 over D2 receptors and 3–10-fold greater D3 affinity than aripiprazole. This D3 selectivity is hypothesised to underlie potential advantages for negative symptoms, cognitive impairment, and depressive features in schizophrenia and mood disorders, since D3 receptors are concentrated in limbic and cortical regions involved in motivation, reward, and cognition. Cariprazine also acts as a partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A and 5-HT2B receptors. Its two major active metabolites — desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR) — are pharmacologically equipotent to the parent drug and contribute substantially to overall clinical effect.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Tmax 3–6 h; food does not significantly affect bioavailability; can be taken with or without food | Convenient once-daily dosing without food restriction — an advantage over lurasidone and ziprasidone |
| Distribution | 91–97% protein-bound; extensive distribution to tissues | Slightly lower protein binding than some SGAs (>99%); no clinically relevant displacement interactions expected |
| Metabolism | CYP3A4 (major) and CYP2D6 (minor) → DCAR → DDCAR; both active metabolites equipotent; DDCAR exposure 2–3× parent at steady state; CYP2D6 status does not significantly alter total exposure | Strong CYP3A4 inhibitors require dose reduction; strong CYP3A4 inducers not recommended (unclear net effect on total active moieties); CYP2D6 PM status does not require adjustment |
| Elimination | t½: cariprazine 2–5 days, DCAR ~30–38 h, DDCAR 1–3 weeks (314–446 h); effective t½ of total active moieties ~1 week; steady state ~1 week (parent/DCAR), ~3 weeks (DDCAR); post-discontinuation: 50% decline in ~1 week, 90% in ~4 weeks; ~21% excreted in urine | Extremely long effective half-life means dose changes and discontinuation effects play out over weeks; provides some built-in protection against relapse from missed doses but also prolongs adverse reactions after stopping |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Extrapyramidal symptoms (non-akathisia) | 15–20% (schizo, dose-related) | Includes tremor, dystonia, parkinsonism, rigidity, drooling; dose-related (15% at 1.5–3 mg, 19% at 4.5–6 mg in schizo trials); higher than most other SGAs |
| Akathisia | 9–14% (schizo); 10–20% (mania) | Dose-related; the only AE leading to ≥2% discontinuation in bipolar mania trials (2%); may appear weeks after initiation due to metabolite accumulation |
| Insomnia | 11–13% (schizo) | Similar to placebo rate (11%); not clearly dose-related; may overlap with underlying illness |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 5–8% (schizo); 7–13% (bipolar depression) | Met the twice-placebo threshold in bipolar depression trials; usually transient |
| Somnolence / Sedation | 5–10% (schizo); 7–8% (mania) | Met twice-placebo threshold in bipolar mania; less sedating than quetiapine or olanzapine |
| Restlessness | 4–6% (schizo); 7% (bipolar depression) | Related to akathisia spectrum; met twice-placebo threshold in bipolar depression and MDD |
| Constipation | 6–10% (schizo, dose-related) | More common at higher doses |
| Vomiting | 4–5% (schizo); 5–10% (mania) | Met twice-placebo threshold in bipolar mania trials |
| Dyspepsia | 4–5% (schizo); 5–7% (mania) | Met twice-placebo threshold in mania |
| Dizziness | 3–5% (schizo); 5% (MDD adjunct) | Related to orthostatic effects; more common in MDD adjunctive trials |
| Weight gain (≥7% increase) | 8% (schizo 1.5–6mg); 1–3% (bipolar/MDD) | Mean gain +0.8 to +1.0 kg (schizo); +0.5 kg (mania); +0.7 kg (MDD/bipolar depression); moderate metabolic profile |
| Fatigue | 4–6% (MDD adjunct) | Met twice-placebo threshold in one 8-week MDD trial |
| Increased appetite | 3–5% (MDD adjunct) | Met twice-placebo threshold in MDD adjunctive trials |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Neuroleptic malignant syndrome | Very rare | Days to weeks | Immediate discontinuation; ICU supportive care |
| Tardive dyskinesia | Rare | Months to years | Consider discontinuation; screen with AIMS periodically |
| Late-occurring adverse reactions | Unique to cariprazine class | Weeks after initiation (metabolite accumulation) | Monitor for EPS/akathisia for several weeks after dose changes; AE incidence in short-term trials may underestimate longer-term rates |
| Suicidal thoughts/behaviours (MDD/bipolar depression) | See boxed warning | Early weeks or dose changes | Close monitoring in patients <25 years |
| Leukopenia / Neutropenia | Rare | First months | Monitor CBC in patients with pre-existing low WBC |
| Seizures | Rare | Any time | Use with caution in patients with seizure history |
Because DDCAR (the predominant active metabolite) has a half-life of 1–3 weeks and reaches steady state only after approximately 3 weeks, adverse reactions such as akathisia and EPS may first appear several weeks after cariprazine is started or the dose is changed. The FDA specifically warns that short-term trial incidence data may underestimate longer-term rates. Clinicians should continue monitoring for new or worsening adverse effects for at least 4–6 weeks after each dose adjustment.
Drug Interactions
CYP3A4 is responsible for both the formation and elimination of cariprazine’s active metabolites. This creates a complex interaction profile: CYP3A4 inhibitors increase exposure to parent drug while potentially altering metabolite ratios, and the net effect of CYP3A4 inducers is unclear and therefore concomitant use is not recommended. Cariprazine does not significantly inhibit or induce CYP enzymes at therapeutic doses.
Monitoring
- EPS / AkathisiaEach visit; continue for weeks after dose changes
RoutineThe most important monitoring parameter for cariprazine. Due to late-occurring adverse reactions from metabolite accumulation, EPS/akathisia may first appear 2–4 weeks after initiation. Use Barnes Akathisia Scale. AIMS every 6–12 months for tardive dyskinesia. - Fasting Glucose & HbA1cBaseline, 12 weeks, then annually
RoutineGlucose shifts from normal to high were similar between cariprazine and placebo in schizophrenia trials. In long-term studies, 4% with normal baseline HbA1c developed elevated levels. Standard APA/ADA monitoring applies. - Lipid PanelBaseline, 12 weeks, then annually
RoutineLipid shifts were generally similar between cariprazine and placebo across indication trials. - Body Weight & BMIBaseline, monthly for 3 months, then quarterly
RoutineMean weight gain +0.8–1.0 kg in schizophrenia (6 weeks); long-term: +1.2 kg at 12 weeks, +2.5 kg at 48 weeks. Monitor paediatric patients carefully — mean change in z-scores was not clinically significant in trials. - Blood PressureBaseline; periodically
RoutineOrthostatic hypotension was infrequent and not more frequent than placebo. Some diastolic BP increase noted at higher doses. - Suicidality AssessmentWeekly for first 4 weeks, then at dose changes
Trigger-BasedRequired for patients <25 years receiving cariprazine for bipolar depression or MDD per boxed warning. Also applies to paediatric patients with schizophrenia/mania. - CBCIf signs of infection or pre-existing low WBC
Trigger-BasedMonitor in patients with history of drug-induced leukopenia. Discontinue if ANC <1000/mm³.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to cariprazine (reactions include rash, pruritus, urticaria, and symptoms suggestive of angioedema)
Relative Contraindications (Specialist Input Recommended)
- Dementia-related psychosis in elderly — increased mortality; not approved for this population
- Concomitant strong or moderate CYP3A4 inhibitors in paediatric patients — initiation of cariprazine is not recommended in this setting per December 2025 label
- Concomitant CYP3A4 inducers — not recommended due to unclear net effect on active moieties
Use with Caution
- History of seizures or conditions lowering seizure threshold
- Patients at risk for falls — somnolence, motor instability
- Severe hepatic impairment — not studied; use with caution
- Patients at risk for aspiration — dysphagia reported
- Exposure to extreme heat — thermoregulation impairment possible
Antipsychotic drugs increase the all-cause risk of death in elderly patients with dementia-related psychosis (4.5% vs 2.6% in placebo, modal trial duration 10 weeks). Cariprazine is not approved for dementia-related psychosis.
Antidepressants increased the risk of suicidal thoughts and behaviours in paediatric and young adult patients in short-term studies. Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts, especially during initial months or at dose changes.
Patient Counselling
Purpose of Therapy
Cariprazine helps balance dopamine and serotonin activity in the brain. Depending on the condition being treated, it may reduce psychotic symptoms (schizophrenia), stabilise mood (bipolar disorder), or enhance antidepressant effectiveness (depression). Because of the way the body processes this medication, the full benefit may take several weeks to develop.
How to Take
Take cariprazine once daily with or without food. Swallow the capsule whole. Because the medication stays in the body for a long time, it takes several weeks for changes in dose to have their full effect. Similarly, if you stop taking it, the effects will take weeks to fully wear off. Do not stop without discussing with your prescriber.
Sources
- AbbVie Inc. VRAYLAR (cariprazine) Prescribing Information. Revised December 2025. FDA LabelPrimary source for all dosing (including new paediatric indications), indications, contraindications, adverse reaction data, and CYP3A4 interaction tables.
- FDA Clinical Review for Paediatric Supplements (NDA 204370, S-14/S-15/S-16/S-17). December 2025. FDA ReviewDetailed FDA review supporting paediatric schizophrenia and bipolar mania indications, including PBPK modelling for CYP3A4 dose adjustments and juvenile animal toxicology.
- Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a 3-week, randomized, double-blind, placebo-controlled trial. J Affect Disord. 2015;174:296-302. doi:10.1016/j.jad.2014.11.018Pivotal RCT supporting the bipolar mania indication with safety data across the 3–12 mg dose range.
- Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77(3):371-378. doi:10.4088/JCP.15m10070Key trial supporting the MDD adjunctive indication with dose-range and akathisia data.
- Earley W, Burgess MV, Rekeda L, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled Phase 3 study. Am J Psychiatry. 2019;176(6):439-448. doi:10.1176/appi.ajp.2018.18070824Pivotal trial establishing the bipolar depression indication with 1.5 mg and 3 mg dosing data.
- Nemeth G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia. Lancet. 2017;389(10074):1103-1113. doi:10.1016/S0140-6736(17)30060-0Landmark trial demonstrating cariprazine’s superiority over risperidone for predominant negative symptoms, supporting the D3 partial agonism hypothesis.
- American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 3rd edition. Am J Psychiatry. 2021;178(suppl). doi:10.1176/appi.books.9780890424841Current APA guideline including cariprazine among antipsychotic options for schizophrenia.
- Yatham LN, Kennedy SH, Parikh SV, et al. CANMAT and ISBD 2018 guidelines for bipolar disorder management. Bipolar Disord. 2018;20(2):97-170. doi:10.1111/bdi.12609International guideline positioning cariprazine as a first-line option for acute mania and second-line for bipolar depression.
- Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate. J Pharmacol Exp Ther. 2010;333(1):328-340. doi:10.1124/jpet.109.160432Foundational study characterising cariprazine’s unique D3-preferring receptor profile and partial agonist pharmacology.
- Gyertyán T, Kiss B, Sághy K, et al. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine. Neuropsychopharmacology. 2019;44(suppl):S365. doi:10.2147/DDT.S208935Demonstrates that DCAR and DDCAR are pharmacologically equipotent to parent cariprazine across in vitro and in vivo models.
- Periclou AP, Carrothers TJ, Ghahramani P, et al. Population pharmacokinetics of cariprazine and its major metabolites. Eur J Drug Metab Pharmacokinet. 2021;46(1):53-69. doi:10.1007/s13318-020-00650-4Population PK model establishing half-life ranges, time to steady state (~1 week parent, ~3 weeks DDCAR), and confirming CYP2D6 status does not alter total exposure.